The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Determinants of racial disparities in immune-related adverse events (irAE) with checkpoint inhibition (ICI) in melanoma.
 
Milad Ibrahim
No Relationships to Disclose
 
Paola Angulo
No Relationships to Disclose
 
Faisal Fa'ak
No Relationships to Disclose
 
Noha Abdel-Wahab
Honoraria - ChemoCentryx
Consulting or Advisory Role - ChemoCentryx
 
Adi Diab
Honoraria - Array BioPharma
Consulting or Advisory Role - Celgene; CureVac; CytomX Therapeutics; Idera; Memgen therapeutics; Nektar; Pfizer (Inst); Regeneron
Research Funding - Apexigen (Inst); Celgene (Inst); Idera (Inst); Lytix Biopharma (Inst); Lytix Biopharma (Inst); Nektar (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Nektar
 
Janice M. Mehnert
Stock and Other Ownership Interests - Pfizer
Honoraria - EMD Serono; Pfizer/EMD Serono
Consulting or Advisory Role - Bristol-Myers Squibb; celled; Eisai; Merck Sharp & Dohme; Novartis; Sanofi/Regeneron; Sanofi/Regeneron; Seagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); bristol myers squibb (Inst); Incyte (Inst); Kinnate Biopharma (Inst); macrogenics (Inst); macrogenics (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Merck Sharp & Dohme
 
Jeffrey S. Weber
Stock and Other Ownership Interests - Biond; Evaxion Biotech; Instil Bio; NexImmune; OncoC4
Honoraria - Amgen; AstraZeneca; Biond Biologics; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Incyte; Instil Bio; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; NexImmune; Novartis; OncoC4; Oncosec; Pfizer; Regeneron; Roche; Sellas Life Sciences; Takeda; Ultimovacs; WindMIL
Consulting or Advisory Role - Amgen; AstraZeneca; Biond Biologics; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Daiichi Sankyo; Genentech; GlaxoSmithKline; Idera; Incyte; Instil Bio; Jounce Therapeutics; Kirin Pharmaceuticals; Merck; Moderna Therapeutics; NexImmune; Novartis; OncoC4; Oncosec; Pfizer; Protean Biodiagnostics; Roche; Sellas Life Sciences; Ultimovacs; WindMIL
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - named on a patent for 41BB induced TIL by Moffitt Cancer Center; named on a patent from Biodesix for a PD-1 antibody biomarker; Named on a patent submitted by Moffitt Cancer Center for an IPILIMUMAB biomarker
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celldex; Genentech; GlaxoSmithKline; Merck; Novartis; Roche
 
Amanda Lund
Consulting or Advisory Role - AGS Therapeutics
 
Markus Schober
No Relationships to Disclose
 
Judy Zhong
No Relationships to Disclose
 
Iman Osman
Employment - Dracen (I)
Leadership - Dracen (I); Dracen (I)